JP2005511632A5 - - Google Patents

Download PDF

Info

Publication number
JP2005511632A5
JP2005511632A5 JP2003545300A JP2003545300A JP2005511632A5 JP 2005511632 A5 JP2005511632 A5 JP 2005511632A5 JP 2003545300 A JP2003545300 A JP 2003545300A JP 2003545300 A JP2003545300 A JP 2003545300A JP 2005511632 A5 JP2005511632 A5 JP 2005511632A5
Authority
JP
Japan
Prior art keywords
receptor agonist
cannabinoid receptor
medicament
acceptable salt
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003545300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005511632A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2002/002108 external-priority patent/WO2003043619A1/en
Publication of JP2005511632A publication Critical patent/JP2005511632A/ja
Publication of JP2005511632A5 publication Critical patent/JP2005511632A5/ja
Pending legal-status Critical Current

Links

JP2003545300A 2001-11-23 2002-11-20 胃食道逆流疾患の治療のための新しい使用 Pending JP2005511632A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0103936 2001-11-23
PCT/SE2002/002108 WO2003043619A1 (en) 2001-11-23 2002-11-20 New use for the treatment of gastroesophageal reflux disease

Publications (2)

Publication Number Publication Date
JP2005511632A JP2005511632A (ja) 2005-04-28
JP2005511632A5 true JP2005511632A5 (https=) 2006-01-12

Family

ID=20286096

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003545300A Pending JP2005511632A (ja) 2001-11-23 2002-11-20 胃食道逆流疾患の治療のための新しい使用

Country Status (20)

Country Link
US (1) US7358245B2 (https=)
EP (1) EP1453497A1 (https=)
JP (1) JP2005511632A (https=)
KR (1) KR20050044582A (https=)
CN (1) CN1610542A (https=)
AR (1) AR037299A1 (https=)
AU (1) AU2002353700A1 (https=)
BR (1) BR0214319A (https=)
CA (1) CA2466916A1 (https=)
HU (1) HUP0402080A3 (https=)
IL (1) IL161748A0 (https=)
IS (1) IS7272A (https=)
MX (1) MXPA04004774A (https=)
NO (1) NO20042613L (https=)
NZ (1) NZ532844A (https=)
PL (1) PL369402A1 (https=)
RU (1) RU2280443C2 (https=)
TW (1) TW200407110A (https=)
WO (1) WO2003043619A1 (https=)
ZA (1) ZA200403785B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06004434A (es) * 2003-10-24 2006-06-20 Solvay Pharm Gmbh Usos medicos novedosos de compuestos que muestran actividad antagonista cb1 y tratamiento de combinacion que involucra tales compuestos.
WO2005060971A1 (en) * 2003-12-18 2005-07-07 Astrazeneca Ab Treatment of reflux-related diseases
SE0303490D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use V
JP2008517976A (ja) 2004-10-25 2008-05-29 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング Cb1カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病1型、肥満及び関連症状の治療用の医薬組成物
EP1827393A4 (en) * 2004-12-09 2012-04-18 Insys Therapeutics Inc AT ROOM TEMPERATURE, STABLE DRONABINOL FORMULATIONS
WO2008019146A2 (en) * 2006-08-04 2008-02-14 Insys Therapeutics Inc. Aqueous dronabinol formulations
JP2010535774A (ja) * 2007-08-06 2010-11-25 インシス セラピューティクス インコーポレイテッド 経口カンナビノイド液体製剤および治療方法
JP2010540618A (ja) * 2007-10-02 2010-12-24 アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド 幼児の成長および発達を増大するための内在性カンナビノイド
US20090208588A1 (en) * 2008-02-19 2009-08-20 Roger Wayne Brown GERD carbohydrate compositions
CN103588672A (zh) * 2013-10-28 2014-02-19 史克勇 一种治疗癌性疼痛的药物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
WO1997029079A1 (en) * 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
CA2340445A1 (en) 1998-05-04 1999-11-11 The University Of Connecticut Novel analgesic and immunomodulatory cannabinoids
US6348498B1 (en) 1998-05-29 2002-02-19 Neurosciences Research Foundation, Inc. Control of pain with endogenous cannabinoids
GB9923738D0 (en) 1999-10-07 1999-12-08 Nestle Sa Nutritional composition
IL132661A (en) * 1999-10-31 2008-11-26 Raphael Mechoulam Agonists specific for peripheral cannabinoid receptors
SE9904507D0 (sv) * 1999-12-09 1999-12-09 Astra Ab New compounds
ES2291323T3 (es) * 2000-06-15 2008-03-01 Schering Corporation Antagonistas de receptores de trombina.
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
FR2816938B1 (fr) 2000-11-22 2003-01-03 Sanofi Synthelabo Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant
US20020077322A1 (en) * 2000-12-15 2002-06-20 Ayoub George S. Protection of neurons against glutamate-induced damage in glaucoma and other conditions

Similar Documents

Publication Publication Date Title
CN105007947B (zh) 固溶体组合物及其在心血管疾病中的用途
US20110237563A1 (en) Fast dissolving drug delivery systems
JP5712452B2 (ja) 診断された呼吸疾患を有する患者もしくは診断未確定の呼吸疾患を有する患者におけるオピオイド鎮痛薬の投与に関連する危険性を減少するための方法および組成
JP2005511632A5 (https=)
TW201912153A (zh) 用於治療b型肝炎的化合物、醫藥組合物及方法
CN101939001B (zh) 用于治疗卵巢癌的含有紫杉醇的组合
EP4297868A1 (en) Use of aprepitant for treating alzheimer's disease
JP2007512273A (ja) ベータ−3−アドレノセプター作用薬及びプロスタグランジン代謝に影響を及ぼす活性物質から成る医薬組成物
US10682343B2 (en) Snoring treatment
JP2001520678A (ja) 睡眠無呼吸症候群の治療に有効な医薬の製造への特異的5ht▲下2▼レセプター拮抗薬の使用
US20050101607A1 (en) Pharmaceutical composition containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha reductase inhibitor
RU2004114843A (ru) Новое применение для лечения заболеваний гастроэзофагеальной рефлюксной болезни
KR20020070525A (ko) 디아미노트리플루오로메틸피리딘의 유도체를 함유하는소화기 질환 치료제 또는 예방제
CN107073015B (zh) 用于治疗吸烟者中的非小细胞肺癌的维利帕尼与卡铂和紫杉醇的组合
JP5042625B2 (ja) 抗炎症剤として有用なα−アミノアミド誘導体
CA2464309A1 (en) Combinations comprising a selective cyclooxygenase-2 inhibitor
US20050154041A1 (en) Pharmaceutical composition consisting of a beta-3-adrenoceptor agonist and alpha-agonist
AU2007325972A1 (en) S-nitrosothiol compounds and related derivatives
JP2016503035A (ja) 肝疾患または肝障害の治療のための使用および方法
EP3965823B1 (en) Use of gold nanoclusters in treating hypercholesterolemia or hypercholesterolemia-associated diseases
CN102781437A (zh) 阿戈美拉汀在得到预定治疗强迫性障碍(ocd)的药物中的用途
CN117379423A (zh) 依达拉奉在自闭症谱系障碍治疗中的应用
CN101291660A (zh) 恢复正常呼吸节律的基于s-亚硝基硫醇的复方药品
CN107496426A (zh) 含伊马替尼或其药学上可接受的盐作为有效成分的用于治疗或预防血管渗透性疾病的组合物
CN1323661C (zh) 脂酶抑制剂的用途